Actuate Therapeutics to host KOL event on Phase 2 elraglusib data

Actuate Therapeutics (ACTU) will host an in-person key opinion leader event, during the 2025 American Society of Clinical Oncology annual meeting, to discuss the elraglusib topline clinical data from the randomized Phase 2 study. The event will feature a fireside discussion moderated by Daniel Schmitt, President & Chief Executive Officer of Actuate, and will include four distinguished KOLs: Tanios Bekaii-Saab, MD, FACP, Mayo Clinic College of Medicine and Science, Devalingam Mahalingam, MD, Northwestern University Feinberg School of Medicine, Rachna Shroff, MD, MS, FASCO, University of Arizona Cancer Center, and Colin Weekes, MD, PhD, Massachusetts General Hospital. The discussion will focus on the clinical relevance and potential impact of the study’s findings on current treatment paradigms, offering expert insights into how these results may shape future therapeutic strategies in mPDAC for patients and clinicians.